Drugmakers look to alternative suppliers after draft U.S. legislation, FT says

Western pharmaceutical companies are looking into alternative suppliers after the release of a draft U.S. legislation that is seeking to restrict a Chinese drug developer and manufacturer over national security concerns, Oliver Barnes, Ian Johnston, and Eleanor Olcott of The Financial Times says. The Biosecure Act would prohibit U.S. companies receiving federal grant money from working with four Chinese biotech companies, including WuXi AppTec and WuXi Biologics. Eli-Lilly (LLY), Vertex Pharmaceuticals (VRTX), and BeiGene (BGNE), among others, have been discussing with rival contract manufacturers to diversify production, several people familiar with discussions said. ArriVent BioPharma (AVBP) and Dianthus Therapeutics (DNTH) are also exploring alternative manufacturing options.